When developing a training curriculum for new clinical research coordinators, which adult learning principle should be prioritized to ensure maximum engagement and retention?
A. Presenting all theoretical content before any practical application
B. Incorporating learners’ prior healthcare experiences and relating new GCP concepts to familiar scenarios
C. Using standardized lectures regardless of learner background
D. Limiting hands-on activities to docus on memorization of regulations
B
A new clinical research professional is mentoring a new coordinator who struggles with informed consent procedures. Which mentoring approach demonstrates best practices?
A. Completing the consent proves for the mentee to demonstrate efficiency
B. Observing the mentee’s consent process, providing specific feedback, and role-playing scenarios together
C. Referring the mentee to online modules without follow-up discussion
D. Requiring the mentee to memorize the entire consent form verbatim
B
According to ICH-GCO E6(R2), which statement best describes the sponsor’s responsibility for investigator oversight?
A. Sponsor must conduct in-person monitoring visits for every enrolled subject
B. Sponsors should implement a risk-based approach to monitoring that is proportionate to study risks and complexity
C. Sponsors are only required to review final study reports without interim oversight
D. Sponsors must delegate all monitoring activities to the investigator
B
When evaluating a clinical research coordinator’s competency in protocol adherence, which assessment method provides the most comprehensive data?
A. A single written examination on protocol content
B. Self-assessment surveys completed by coordinator
C. Multiple methods including direct observation, case reviews, and structured competency assessments over time
D. Counting the number of protocol deviations without contextual analysis
C
A research site is preparing for an FDA inspection. Which communication strategy best prepares the team while maintaining regulatory compliance?
A. Coaching staff to provide minimal information and defer all questions to the principal investigator
B. Conducting mock inspections, reviewing SOPs, ensuring staff understand their roles, and emphasizing honest, accurate responses
C. Hiding documents that might reveal protocol deviations
D. Instructing staff to memorize scripted answers to anticipated questions
B
In curriculum development for clinical research training, which sequencing approach best supports progressive skill building?
A. Teaching complex statistical analysis before basic study design concepts
B. Beginning with foundational GCP principles, progressing to protocol-specific procedures, then advancing to problem-solving scenarios
C. Randomizing content delivery to maintain learner interest
D. Starting with rare adverse event reporting before routine study procedures
B
Which mentoring technique is most effective is most effective when a mentee repeatedly makes the same documentation errors in source documents?
A. Publicly correcting errors during team meetings to discourage repetition
B. Using the error as a teaching moment: reviewing root causes, demonstrating correct documentation, and implementing a short-term review system
C. Removing the mentee’s documentation responsibilities permanently
D. Reporting the mentee to the IRB without additional training
B
According to 21 CFR Part 50, which is NOT required in the informed consent process?
A. A statement that participation is voluntary and refusal involves no penalty
B. A description of reasonably foreseeable risks or discomforts
C. A guarantee that the experimental treatment will be more effective than standard of care
D. An explanation of whom to contact for questions about the research
C
When designing an evaluation tool for clinical research site performance, which metric best reflects quality rather than just quantity?
A. Total number of subjects screened regardless of eligibility
B. Query resolution time, protocol adherence rate, and data quality metrics
C. Number of studies conducted without considering outcomes
D. Coordinator availability hours only
B
A clinical research professional must communicate a serious adverse event to multiple stakeholders. Which approach demonstrates proper regulatory compliance and communication hierarchy?
A. Posting the event details on social media first to inform the public
B. Following the protocol-specified timeline to notify the sponsor, IRB, and regulatory authorities per regulations, maintaining confidentiality
C. Waiting until the study concludes to report all adverse events together
D. Notify only the sponsor and excluding the IRB
B
Which adult learning principle is most critical when training experienced nurses transitioning to clinical research roles?
A. Treating them as novices with no relevant prior knowledge
B. Recognizing their clinical expertise while building on it to develop research-specific competencies
C. Requiring them to complete the same entry-level training as those without healthcare backgrounds
D. Focusing exclusively on regulatory compliance without connecting to clinical practice
B
During a curriculum development process for multi-site network, which approach ensures consistent training quality across locations?
A. Allowing each site complete autonomy without standardization
B. Developing standardized core content with site-specific adaptations, regular trainer calibration, and competency assessment
C. Using only written materials without interactive components
D. Training only principal investors and expecting knowledge cascade
B
A mentor observes that their mentee becomes defensive when receiving constructive feedback. Which approach best addresses this situation?
A. Avoiding all negative feedback to maintain the relationship
B. Using the “sandwich” approach occasionally, but primarily focusing on specific behaviors, maintaining supportive tone, and collaborating on improvement plans
C. Escalating to human resources immediately without attempting dialogue
D. Providing only written feedback to avoid personal interaction
B
According to 21 CFR Part 312, what is the sponsor’s responsibility regarding and IND safety report?
A. Safety reports are optional for sponsors in all circumstances
B. Sponsors must submit IND safety reports for serious and unexpected suspected adverse reactions within 15 calendar days
C. Safety reports should be submitted only at the annual IND report
D. Sponsors report safety information only to investigators, not to FDA
B
Which evaluation method best assesses a clinical research coordinator’s ability to identify and respond to protocol deviations in real-time?
A. Annual written examinations only
B. Scenario-based simulations that mimic actual protocol deviation situations with real-time decision-making
C. Reviewing theoretical knowledge of deviation definitions
D. Counting historical deviation without analyzing coordinator response
B
When communicating complex protocol amendments to research staff, which strategy ensures comprehension and compliance?
A. Emailing the amendment without discussion and assuming understanding
B. Conducting interactive training sessions, providing written summaries, assessing comprehension, and documenting training
C. Announcing changes during brief hallway conversations
D. Expecting staff to independently read and implement changes without guidance
B
A clinical research training program aims to develop critical thinking skills. Which instructional strategy best achieves this goal?
A. Requiring memorization of GCP guidelines word-for-word
B. Using case-based learning with complex scenarios requiring analysis, judgement, and decision-making
C. Providing only multiple-choice tests without applies scenarios
D. Lecturing without opportunity for questions and discussion
B
What is significant equity interest?
If the PI gets interest/stock options or any other financial and equity interest during the time of the study and 1 year following completion of the study.
For a publicly traded company, this means more than $50k to PI, spouse or children.
What is a significant payment to an investigator in a covered trial?
Monetary value over $25k during the trial or up to 1 year after trial completion
What are the 5 key aspects of pre-clinical studies?
1) Help establish boundaries for the safe use of treatment when human testing begins
2) Studies designed to evaluate compounds for potential pharmacologic use
3) Generally performed in animals
4) Evaluate the possibility of long-term, adverse events: onset of cancer, interference with reproduction or the induction of birth defects etc.
5) When sufficient data are obtained to warrant study in humans subjects, a sponsor submits an IND
What are the 4 key aspects of phase 1 studies?
1) Small trials with healthy subjects, purpose is to determine pharmacokinetics and maximum tolerated dose
2) Conducted to determine the appropriate dose range with regard to safety and toxicity (not to evaluate efficacy)
3) Conducted in a limited number (20-80) of health volunteers or patients (cancer, AIDS)
4) Many compounds are abandoned in this phase because of safety/toxicity problems
What are the 5 key aspects of phase II studies?
1) Initial demonstration of efficacy in patients, short-term safety information
2) Conducted in a relatively limited number (100-300) patients who have the disease
3) Often involve hospitalized patients who can be closely monitored
4) Many focus on dose-response, dosing schedule, or other issues related to preliminary safety and efficacy
5) Takes about 1 to 3 years to complete
What are the 5 key aspects of phase III studies?
1) Use in large numbers of patients, long-term safety data
2) Conducted in larger (several hundred to several thousand) and more diverse groups for whom the drug is ultimately intended
3) Make comparisons between new treatment and standard therapy or placebo
4) Study a drug used by practicing physicians in the same manner as it would be used after marketing
5) Takes about 2 to 5 years to complete
-
The Nuremberg Code17
-
The Belmont Report24
-
The Declaration of Helsinki7
-
ICH Harmonized Guideline for Good Clinical Practice, E6(R3)24
-
21 CFR Part 111
-
IND Reporting Timelines27
-
IDE Reporting Timelines22
-
Practice Questions23
-
Part 46, Industry GCP, and ICH Reporting Timelines16
-
Study Guide171
-
Regulatory Guide75
-
General Knowledge51
-
Practice Test107
-
Informed Consent15
-
FDA Forms8
-
Title 21 Definitions16
